KR-31831, a new synthetic anti-ischemic agent, inhibits in vivo and in vitro angiogenesis
- Authors
- Yi, EY[Yi, Eui-Yeun]; Park, SY[Park, Shi-Young]; Song, HS[Song, Hyun Seok]; Son, MJ[Son, Myung Jin]; Yi, KY[Yi, Kyu-Yang]; Yoo, SE[Yoo, Sung-En]; Kim, YJ[Kim, Yung-Jin]
- Issue Date
- 31-Oct-2006
- Publisher
- KOREAN SOC MED BIOCHEMISTRY MOLECULAR BIOLOGY
- Citation
- EXPERIMENTAL AND MOLECULAR MEDICINE, v.38, no.5, pp.502 - 508
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- EXPERIMENTAL AND MOLECULAR MEDICINE
- Volume
- 38
- Number
- 5
- Start Page
- 502
- End Page
- 508
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/86602
- ISSN
- 1226-3613
- Abstract
- Angiogenesis is considered to be an integral process to the growth and spread of solid tumors. Anti-angio genesis therapy recently has been found to be one of the most promising anti-cancer therapeutic strategies. In this study, we provide several lines of evidences showing that KR-31831, a new benzopyran derivative, has anti-angiogenic activities. KR-31831 inhibited the proliferation, migration, invasion and tube formation of bovine aortic endothelial cells (BAECs), and suppressed the release of matrix metalloproteinase-2 (MMP-2) of BAECs. KR-31831 also inhibited in vivo angiogenesis in mouse Matrigel plug assay. Furthermore, the mRNA expressions of basic fibroblast growth factor (bFGF), fibroblast growth factor receptor-2 (FGFR-2), and vascular endothelial growth factor receptor-2 (VEGFR-2) were decreased by KR-31831. Taken together, these results suggest that KR-31831 acts as a novel angiogenesis inhibitor and might be useful for treating hypervascularized cancers.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/86602)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.